Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma

While the clinical benefit of MEK inhibitor (MEKi)-based therapy is well established in Raf mutant malignancies, its utility as a suppressor of hyperactive MAPK signaling in the absence of mutated Raf or Ras, is an area of ongoing research. MAPK activation is associated with loss of ERα expression a...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Hou, June Y., Rodriguez-Gabin, Alicia, Samaweera, Leleesha, Hazan, Rachel, Goldberg, Gary L., Horwitz, Susan Band, McDaid, Hayley M.
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2013
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3563537/
https://ncbi.nlm.nih.gov/pubmed/23390495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0054103
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items